Blackcrane Capital’s Takeda Pharmaceutical TAK Stock Holding History

Blackcrane Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$3.15M	Sell	30,201 -937	-3%	-$13.8K	19.29%	2
2021 Q4	$3.75M	Buy	31,138 +2,860	+10%	+$40.1K	5.2%	7
2021 Q3	$3.16M	Buy	28,278 +6,809	+32%	+$114K	4.02%	7
2021 Q2	$2.58M	Buy	21,469 +6,898	+47%	+$117K	3.15%	11
2021 Q1	$1.72M	Sell	14,571 -20,665	-59%	-$372K	2.72%	10
2020 Q4	$641K	Buy	35,236 +9,513	+37%	+$167K	1.26%	11
2020 Q3	$459K	Hold	25,723	–	–	1.07%	8
2020 Q2	$461K	Sell	25,723 -109,734	-81%	-$1.97M	0.52%	9
2020 Q1	$2.06M	Sell	135,457 -37,251	-22%	-$675K	1.88%	9
2019 Q4	$3.41M	Hold	172,708	–	–	2.72%	9
2019 Q3	$2.97M	Sell	172,708 -247	-0.1%	-$4.27K	3.95%	9
2019 Q2	$3.06M	Sell	172,955 -16,594	-9%	-$302K	3.88%	9
2019 Q1	$3.86M	Buy	+189,549	New	+$3.81M	5.16%	8

Other funds holding TAK

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Blackcrane Capital's TAK Position: Q1 2022 in Review

Blackcrane Capital reduced its Takeda Pharmaceutical (TAK) stake by 3% in Q1 2022, selling an estimated $13.8K and leaving 30,201 shares worth $3.15M. The position accounts for 19.29% of the portfolio, ranked #2.

Blackcrane Capital first reported a position in TAK in Q1 2019 and has held it in 13 quarters since. The position peaked at $3.86M in Q1 2019. 287 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

Blackcrane Capital held 30,201 shares of Takeda Pharmaceutical worth $3.15M as of Q1 2022.
Blackcrane Capital sold 937 Takeda Pharmaceutical shares in Q1 2022, an estimated $13.8K.
Takeda Pharmaceutical made up 19.29% of Blackcrane Capital's portfolio in Q1 2022, its #2 holding.
Blackcrane Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 13 quarters since.
Blackcrane Capital's Takeda Pharmaceutical position peaked at $3.86M in Q1 2019.
287 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on Blackcrane Capital's 13F filing for Q1 2022, filed 12 May 2022.